Bank Julius Baer & Co’s Adaptive Biotechnologies ADPT Stock Holding History

Bank Julius Baer & Co’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-800	Closed	-$22K	–	581
2021 Q4	$22K	Hold	800	–	–	﹤0.01%	731
2021 Q3	$27K	Sell	800 -59,112	-99%	-$2.14M	﹤0.01%	728
2021 Q2	$2.45M	Sell	59,912 -194,655	-76%	-$7.57M	0.02%	261
2021 Q1	$10.2M	Buy	254,567 +142,627	+127%	+$7.72M	0.08%	153
2020 Q4	$6.62M	Buy	111,940 +56,545	+102%	+$2.92M	0.05%	169
2020 Q3	$2.69M	Buy	55,395 +19,406	+54%	+$816K	0.03%	192
2020 Q2	$1.74M	Sell	35,989 -79	-0.2%	-$2.88K	0.02%	213
2020 Q1	$1M	Buy	+36,068	New	+$1.01M	0.02%	227

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Bank Julius Baer & Co's ADPT Position: Q1 2022 in Review

Bank Julius Baer & Co sold out of Adaptive Biotechnologies (ADPT) in Q1 2022, closing a stake of 800 shares — an estimated $22K sold.

Bank Julius Baer & Co first reported a position in ADPT in Q1 2020 and held it in 8 quarters. The position peaked at $10.2M in Q1 2021. 221 funds tracked by Wall St. Rank hold ADPT as of Q1 2022.

Bank Julius Baer & Co reported no remaining Adaptive Biotechnologies position as of Q1 2022 after selling out during the quarter.
Bank Julius Baer & Co sold 800 Adaptive Biotechnologies shares in Q1 2022, an estimated $22K.
Bank Julius Baer & Co first reported a position in Adaptive Biotechnologies in Q1 2020 and held it in 8 quarters.
Bank Julius Baer & Co's Adaptive Biotechnologies position peaked at $10.2M in Q1 2021.
221 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2022.

Based on Bank Julius Baer & Co's 13F filing for Q1 2022, filed 9 May 2022.